Bionano Genomics (NASDAQ:BNGO) Shares to Reverse Split on Monday, January 27th

Bionano Genomics, Inc. (NASDAQ:BNGO)’s stock is set to reverse split on Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 24th.

Bionano Genomics Stock Performance

Bionano Genomics stock traded down $0.05 during midday trading on Thursday, hitting $0.13. 31,894,418 shares of the company’s stock were exchanged, compared to its average volume of 19,639,521. The stock has a market cap of $15.47 million, a price-to-earnings ratio of -0.06 and a beta of 2.22. The firm’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.38. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43. Bionano Genomics has a 12-month low of $0.13 and a 12-month high of $1.36.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.

Institutional Trading of Bionano Genomics

Institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP purchased a new stake in Bionano Genomics during the third quarter worth about $46,000. Geode Capital Management LLC raised its position in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after acquiring an additional 283,639 shares during the last quarter. Armistice Capital LLC acquired a new position in Bionano Genomics during the second quarter worth about $1,138,000. Finally, Carret Asset Management LLC raised its position in Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after acquiring an additional 40,055 shares during the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.